These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
233 related articles for article (PubMed ID: 22180194)
1. Aldehyde dehydrogenase 1-positive cells in axillary lymph node metastases after chemotherapy as a prognostic factor in patients with lymph node-positive breast cancer. Sakakibara M; Fujimori T; Miyoshi T; Nagashima T; Fujimoto H; Suzuki HT; Ohki Y; Fushimi K; Yokomizo J; Nakatani Y; Miyazaki M Cancer; 2012 Aug; 118(16):3899-910. PubMed ID: 22180194 [TBL] [Abstract][Full Text] [Related]
2. Expression of ALDH1 in axillary lymph node metastases is a prognostic factor of poor clinical outcome in breast cancer patients with 1-3 lymph node metastases. Nogami T; Shien T; Tanaka T; Nishiyama K; Mizoo T; Iwamto T; Ikeda H; Taira N; Doihara H; Miyoshi S Breast Cancer; 2014 Jan; 21(1):58-65. PubMed ID: 22407396 [TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of occult axillary lymph node metastases after chemotherapy-induced pathologic complete response of cytologically proven axillary lymph node metastases from breast cancer. Loya A; Guray M; Hennessy BT; Middleton LP; Buchholz TA; Valero V; Sahin AA Cancer; 2009 Apr; 115(8):1605-12. PubMed ID: 19197997 [TBL] [Abstract][Full Text] [Related]
4. Evaluation of aldehyde dehydrogenase 1 and transcription factors in both primary breast cancer and axillary lymph node metastases as a prognostic factor. Ito M; Shien T; Omori M; Mizoo T; Iwamoto T; Nogami T; Motoki T; Taira N; Doihara H; Miyoshi S Breast Cancer; 2016 May; 23(3):437-44. PubMed ID: 25599843 [TBL] [Abstract][Full Text] [Related]
5. Aldehyde dehydrogenase 1 expression is a predictor of poor prognosis in node-positive breast cancers: a long-term follow-up study. Yoshioka T; Umekita Y; Ohi Y; Souda M; Sagara Y; Sagara Y; Sagara Y; Rai Y; Tanimoto A Histopathology; 2011 Mar; 58(4):608-16. PubMed ID: 21371077 [TBL] [Abstract][Full Text] [Related]
6. Sentinel lymph node biopsy examination for breast cancer patients with clinically negative axillary lymph nodes after neoadjuvant chemotherapy. Kinoshita T; Takasugi M; Iwamoto E; Akashi-Tanaka S; Fukutomi T; Terui S Am J Surg; 2006 Feb; 191(2):225-9. PubMed ID: 16442950 [TBL] [Abstract][Full Text] [Related]
7. [ALDH1-positive cells in axillary lymph node metastases after chemotherapy as a prognostic factor in patients with node-positive breast cancer]. Fujimori T; Sakakibara M Nihon Rinsho; 2012 Sep; 70 Suppl 7():454-9. PubMed ID: 23350441 [No Abstract] [Full Text] [Related]
8. The expression of aldehyde dehydrogenase 1 in invasive primary breast tumors and axillary lymph node metastases is associated with poor clinical prognosis. Dong Y; Bi LR; Xu N; Yang HM; Zhang HT; Ding Y; Shi AP; Fan ZM Pathol Res Pract; 2013 Sep; 209(9):555-61. PubMed ID: 23916993 [TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of pathological response of primary tumor and metastatic axillary lymph nodes after neoadjuvant chemotherapy for locally advanced breast carcinoma. Machiavelli MR; Romero AO; Pérez JE; Lacava JA; Domínguez ME; Rodríguez R; Barbieri MR; Romero Acuña LA; Romero Acuña JM; Langhi MJ; Amato S; Ortiz EH; Vallejo CT; Leone BA Cancer J Sci Am; 1998; 4(2):125-31. PubMed ID: 9554929 [TBL] [Abstract][Full Text] [Related]
10. Can breast MRI predict axillary lymph node metastasis in women undergoing neoadjuvant chemotherapy. Javid S; Segara D; Lotfi P; Raza S; Golshan M Ann Surg Oncol; 2010 Jul; 17(7):1841-6. PubMed ID: 20143266 [TBL] [Abstract][Full Text] [Related]
11. Sentinel lymph node biopsy after neoadjuvant chemotherapy is accurate in breast cancer patients with a clinically negative axillary nodal status at presentation. Gimbergues P; Abrial C; Durando X; Le Bouedec G; Cachin F; Penault-Llorca F; Mouret-Reynier MA; Kwiatkowski F; Maublant J; Tchirkov A; Dauplat J Ann Surg Oncol; 2008 May; 15(5):1316-21. PubMed ID: 18311507 [TBL] [Abstract][Full Text] [Related]
12. Pathologic tumor response in the breast following neoadjuvant chemotherapy predicts axillary lymph node status. Kuerer HM; Newman LA; Buzdar AU; Dhingra K; Hunt KK; Buchholz TA; Binkley SM; Strom EA; Ames FC; Ross MI; Feig BW; McNeese MD; Hortobagyi GN; Singletary SE Cancer J Sci Am; 1998; 4(4):230-6. PubMed ID: 9689981 [TBL] [Abstract][Full Text] [Related]
13. [Predictors of axillary node metastasis at breast surgery after neoadjuvant chemotherapy in patients with pre- chemotherapy-sentinel node positive breast cancer]. Tokita H; Aruga T; Yamashita T; Saji S; Suzuki E; Horiguchi K; Kitagawa D; Sekine S; Horiguchi S; Hirashima Y; Kuroi K Gan To Kagaku Ryoho; 2011 Oct; 38(10):1639-45. PubMed ID: 21996959 [TBL] [Abstract][Full Text] [Related]
14. Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer. Gajdos C; Tartter PI; Estabrook A; Gistrak MA; Jaffer S; Bleiweiss IJ J Surg Oncol; 2002 May; 80(1):4-11. PubMed ID: 11967899 [TBL] [Abstract][Full Text] [Related]
15. Clinical significance of axillary microresiduals after neoadjuvant chemotherapy in breast cancer patients with cytologically proven metastases. Sakakibara M; Nagashima T; Kadowaki M; Onai Y; Fujimori T; Yokomizo J; Suzuki H; Fushimi K; Nakatani Y; Miyazaki M Ann Surg Oncol; 2009 Sep; 16(9):2470-8. PubMed ID: 19588201 [TBL] [Abstract][Full Text] [Related]
16. Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicin-based chemotherapy for breast cancers. Tanei T; Morimoto K; Shimazu K; Kim SJ; Tanji Y; Taguchi T; Tamaki Y; Noguchi S Clin Cancer Res; 2009 Jun; 15(12):4234-41. PubMed ID: 19509181 [TBL] [Abstract][Full Text] [Related]
17. Sentinel node biopsy in breast cancer patients treated with neoadjuvant chemotherapy. Tanaka Y; Maeda H; Ogawa Y; Nishioka A; Itoh S; Kubota K; Ue H; Nakatani K; Sasaguri S Oncol Rep; 2006 Apr; 15(4):927-31. PubMed ID: 16525681 [TBL] [Abstract][Full Text] [Related]
18. Is regional lymph node irradiation necessary in stage II to III breast cancer patients with negative pathologic node status after neoadjuvant chemotherapy? Daveau C; Stevens D; Brain E; Berges O; Villette S; Moisson P; Gardner M; De la Lande B; Lasry S; Labib A; Le Scodan R Int J Radiat Oncol Biol Phys; 2010 Oct; 78(2):337-42. PubMed ID: 20171795 [TBL] [Abstract][Full Text] [Related]
19. Pathobiology of preoperative chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel (NSABP) protocol B-18. Fisher ER; Wang J; Bryant J; Fisher B; Mamounas E; Wolmark N Cancer; 2002 Aug; 95(4):681-95. PubMed ID: 12209710 [TBL] [Abstract][Full Text] [Related]
20. Percent positive axillary lymph node metastasis predicts survival in patients with non-metastatic breast cancer. Lale Atahan I; Yildiz F; Ozyigit G; Sari S; Gurkaynak M; Selek U; Hayran M Acta Oncol; 2008; 47(2):232-8. PubMed ID: 17924207 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]